SEC Filings
Abbott CEO's Change-In-Control Agreement Will Expire While Other Executives Get Extensions
The other named executive officers' agreements will run through December 31, 2028, under an existing extension provision.
SEC Filings
The other named executive officers' agreements will run through December 31, 2028, under an existing extension provision.
SEC Filings
Weekly dosing reached 99% suppression, while the ongoing study will measure weight, fat and lean mass at week 24.
SEC Filings
Vir expects approximately $140.4 million after costs, with additional proceeds possible if underwriters exercise their option.
SEC Filings
The company expects about $93.5 million after offering costs as preliminary ersodetug study findings await complete analysis.
SEC Filings
Ivonescimab missed the trial's main survival goal, while Summit plans to keep developing the drug across other cancers.
SEC Filings
The new holding accounted for about 25% of the disclosed portfolio, while Fairfax exited Orla Mining.
SEC Filings
The disclosed US stock portfolio grew to $54.5 billion, while the investment firm reduced its Cerebras stake.
SEC Filings
Overdue domestic card loans totaled $10.1 billion, with uncollectible billed interest and fees reducing revenue separately.
SEC Filings
Shareholders would receive Transocean stock, while Valaris added merger information to limit litigation costs and delay risks.
SEC Filings
The overlapping ownership reports cover 12,672,350 shares, while Icahn Partners LP sold shares in the open market.
SEC Filings
The investment firm's Nvidia stake roughly doubled in value as its disclosed portfolio fell to $114.3 billion.
SEC Filings
The shareholder reported a 6.45% stake, with the award shares generally subject to a two-year holding requirement.